

# Stephin J Vervoort

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1177290/publications.pdf>

Version: 2024-02-01

24  
papers

1,583  
citations

567281

15  
h-index

610901

24  
g-index

27  
all docs

27  
docs citations

27  
times ranked

2947  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting transcription cycles in cancer. <i>Nature Reviews Cancer</i> , 2022, 22, 5-24.	28.4	59
2	BET Inhibition Enhances TNF-Mediated Antitumor Immunity. <i>Cancer Immunology Research</i> , 2022, 10, 87-107.	3.4	8
3	Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. <i>Leukemia</i> , 2022, 36, 1654-1665.	7.2	9
4	Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia. <i>EMBO Molecular Medicine</i> , 2022, 14, e15203.	6.9	10
5	Epigenetic modulators of B cell fate identified through coupled phenotype-transcriptome analysis. <i>Cell Death and Differentiation</i> , 2022, 29, 2519-2530.	11.2	5
6	SUGAR-seq enables simultaneous detection of glycans, epitopes, and the transcriptome in single cells. <i>Science Advances</i> , 2021, 7, .	10.3	46
7	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. <i>Molecular Cell</i> , 2021, 81, 2183-2200.e13.	9.7	59
8	The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. <i>Cell</i> , 2021, 184, 3143-3162.e32.	28.9	103
9	Loss of erythroblasts in acute myeloid leukemia causes iron redistribution with clinical implications. <i>Blood Advances</i> , 2021, 5, 3102-3112.	5.2	5
10	HOIP limits anti-tumor immunity by protecting against combined TNF and IFN $\gamma$ -induced apoptosis. <i>EMBO Reports</i> , 2021, 22, e53391.	4.5	21
11	Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma. <i>Haematologica</i> , 2021, 106, 2013-2017.	3.5	7
12	Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation. <i>Cell Reports</i> , 2020, 33, 108290.	6.4	4
13	IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. <i>Molecular Therapy</i> , 2020, 28, 2379-2393.	8.2	49
14	CDK13 cooperates with CDK12 to control global RNA polymerase II processivity. <i>Science Advances</i> , 2020, 6, .	10.3	79
15	Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. <i>Nature Immunology</i> , 2020, 21, 914-926.	14.5	114
16	Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion. <i>Cell Reports</i> , 2019, 28, 2784-2794.e5.	6.4	77
17	Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis. <i>Nature Communications</i> , 2019, 10, 1347.	12.8	41
18	Antagonism of IAPs Enhances CAR T-cell Efficacy. <i>Cancer Immunology Research</i> , 2019, 7, 183-192.	3.4	68

#	ARTICLE	IF	CITATIONS
19	Inhibition of Endosteal Vascular Niche Remodeling Rescues Hematopoietic Stem Cell Loss in AML. <i>Cell Stem Cell</i> , 2018, 22, 64-77.e6.	11.1	249
20	Tumor immune evasion arises through loss of TNF sensitivity. <i>Science Immunology</i> , 2018, 3, .	11.9	244
21	BCOR Regulates Cell Fate Transition, Myeloid Differentiation and Leukaemogenesis. <i>Blood</i> , 2018, 132, 3907-3907.	1.4	3
22	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. <i>Cell Reports</i> , 2017, 18, 2162-2174.	6.4	244
23	DOCK8 Drives Src-Dependent NK Cell Effector Function. <i>Journal of Immunology</i> , 2017, 199, 2118-2127.	0.8	18
24	BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2030-2041.	4.1	57